Home / Going-concern warnings / Dermata Therapeutics, Inc.
Filed 2025-08-13 路 Form 10-Q 路 Accession 0001641172-25-023572 nano
Price before filing: $6.11 (2025-08-12 close, split/dividend-adjusted)
Market cap at flag: $6.6M (2025-08-13) 路 Latest: $3.5M (2026-10-16)
| Window | DRMA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -11.5% | +2.3% | -13.7% | 2025-09-12 |
| 90 days | -47.5% | +6.6% | -54.0% | 2025-11-11 |
| 180 days | -73.6% | +8.6% | -82.2% | 2026-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for the one-year period following the date that these financial statements were issued."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure; also within 90 days: Auditor change
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.